HC Wainwright & Co. Reiterates Buy on Immunovant, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Immunovant (NASDAQ:IMVT) and maintained a price target of $51, indicating confidence in the company's future performance.
September 30, 2024 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Immunovant and maintained a $51 price target, suggesting a positive outlook for the company's stock.
The reiteration of a Buy rating and maintenance of a $51 price target by HC Wainwright & Co. suggests confidence in Immunovant's future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100